Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Alex Friedlaender, Vivek Subbiah, Alessandro Russo, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 1, pp. 51-69
Closed Access | Times Cited: 146

Showing 1-25 of 146 citing articles:

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
Karama Makni‐Maalej, Maysaloun Merhi, Varghese Inchakalody, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 292
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 89
Rare molecular subtypes of lung cancer
Guilherme Harada, Soo‐Ryum Yang, Emiliano Cocco, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 4, pp. 229-249
Open Access | Times Cited: 75
Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)
Melanie Janning, Juliane Süptitz, Corinna Albers, et al.
Annals of Oncology (2022) Vol. 33, Iss. 6, pp. 602-615
Open Access | Times Cited: 74
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
Georgia Gomatou, Nikolaos Syrigos, Ηλίας Κοττέας
Cancers (2023) Vol. 15, Iss. 3, pp. 841-841
Open Access | Times Cited: 72
Structure and dynamics of the EGFR/HER2 heterodimer
Xue Bai, Pengyu Sun, Xinghao Wang, et al.
Cell Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 71
Emerging evidence and treatment paradigm of non-small cell lung cancer
Si‐Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 59
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Shaochuan Liu, Qian Sun, Xiubao Ren
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 49
Oncogenic alterations in advanced NSCLC: a molecular super-highway
Alex Friedlaender, M. Pérol, Giuseppe Luigi Banna, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 39
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
Jing Wang, Baizhou Li, Meng Luo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 28
Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials
Wenru Zhang, Mengmeng Wang, Chonghao Ji, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 116930-116930
Open Access | Times Cited: 28
Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review
Maxime Borgeaud, Kaushal Parikh, Giuseppe Luigi Banna, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 7, pp. 973-983
Open Access | Times Cited: 24
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Mengzhao Wang, James Chih‐Hsin Yang, Paul Mitchell, et al.
Cancer Discovery (2022) Vol. 12, Iss. 7, pp. 1676-1689
Open Access | Times Cited: 70
The role of interaction between autophagy and apoptosis in tumorigenesis (Review)
Hongyan Xi, Shuo Wang, Beibei Wang, et al.
Oncology Reports (2022) Vol. 48, Iss. 6
Open Access | Times Cited: 64
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
Rocı́o I.R. Macı́as, Vincenzo Cardinale, Timothy J. Kendall, et al.
Gut (2022), pp. gutjnl-327099
Open Access | Times Cited: 52
Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
Andreas Koulouris, Christos Tsagkaris, Anna Chiara Corriero, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3337-3337
Open Access | Times Cited: 46
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
Zhengbo Song, Yuping Li, Shiqing Chen, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 44
Nanomedicine Combats Drug Resistance in Lung Cancer
Xiuli Zheng, Xiao-Hai Song, Guonian Zhu, et al.
Advanced Materials (2023) Vol. 36, Iss. 3
Closed Access | Times Cited: 36
Potential roles and molecular mechanisms of bioactive ingredients in Curcumae Rhizoma against breast cancer
Peng Zhao, Jianfei Qiu, Chaolan Pan, et al.
Phytomedicine (2023) Vol. 114, pp. 154810-154810
Closed Access | Times Cited: 24
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)
Chao Zhang, Yuxuan Sun, Dingcheng Yi, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 7, pp. 101615-101615
Open Access | Times Cited: 15
Emerging roles of O-GlcNAcylation in protein trafficking and secretion
Jianchao Zhang, Yanzhuang Wang
Journal of Biological Chemistry (2024) Vol. 300, Iss. 3, pp. 105677-105677
Open Access | Times Cited: 12
Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer
Lufeng Zheng, Yuxin Zhang, Shuang Mei, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 7130-7145
Closed Access | Times Cited: 11
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer
Benjamin C. Milgram, Deanna R. Borrelli, Natasja Brooijmans, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study
John V. Heymach, Frans L. Opdam, Minal Barve, et al.
Journal of Clinical Oncology (2025)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top